Illumina is a company that aims to unlock the power of the genome. The company’s products are utilized for applications in numerous sectors, including oncology, reproductive health, agriculture, and other emerging segments. On September 7, 2017, Illumina (NASDAQ: ILMN) announced that it had filed a new patent infringement suit against Premaitha Health PLC in the United Kingdom.
The company is seeking all available remedies, including injunctive relief and damages. The suit alleges that Premaitha’s IONA Test infringed on European Patent “Non-invasive Detection of Fetal Genetic Traits”, which has been licensed exclusively to Illumina by Sequenom Inc.
Illumina and its wholly owned subsidiary, Verinata Health, filed suits against the same company earlier this year. Those suits are still pending.